EUROPA PASA DE TENER DOS TRATAMIENTOS SCLC-ES EN PRIMERA LINEA INMUNOTERAPIA ( ATEZOLIZUMAB
Y DURVALUMAB ) ... A TENER CUATRO ( ATEZOLIZUMAB, DURVALUMAB , SERPLULIMAB Y TISLELIZUMAB ) .
08 julio 2022
Mr. Cozadd Co-Founded JazzPharma , Inc. And Has Served As Chairman And Chief Executive Officer Of Jazz Pharmaceuticals, Inc .
